Search

Your search keyword '"Incardona, Francesca"' showing total 4 results
Start Over Author "Incardona, Francesca" Database OpenAIRE
4 results on '"Incardona, Francesca"'

1. Reproducibility Project: Cancer Biology

Author

Errington, Timothy, Denis, Alexandria, Perfito, Nicole, Tan, Fraser, Lomax, Joelle, Williams, Stephen, Tsui, Rachel, Gunn, William, Iorns, Elizabeth, Nosek, Brian, Acharya, Grishma, Adebamowo, Sally, Afshari, Amirali, Agius, Claire, Aird, Fraser, Allison, Anne, Amitai, Nurith, Anant, Madan, Anderson, Natalie, Ang, Lay-Hong, Antes, Travis, Araiza, Renee, Arora, Deepika, Aza-Blanc, Pedro, Bencsics, Craig, Berry, Deborah, Bhargava, Ajay, Biressi, Stefano, Blocher, Lawrence, Blum, David, Boedeker, Elizabeth, Bower, Lynette, Boyd, Leslie, Brinton, Lindsey, Brown, Claire, Bullenkamp, Jessica, Cai, Steve, Cajka, Tomas, Campos, Jessica, Carraway, Kermit, Carrell, Jacqueline, Carreno, Alberto, Cavadas, Miguel, Chang, Chih-Cheng, Chen, Biao, Chou, James, Chou, Wen-Ko, Chow, Kartoa, Chroscinski, Denise, Chu, Heidi, Cook, Matthew, Coss, Chris, Courville, Pascal, Cowley, Dale, Danet-Desnoyers, Gwenn, Dareng, Eileen, Delgadillo, I., de Morrée, Antoine, Denike, Trisha, Denson, Sarah, Dhami, Gurpreet, Ding, Jianhua, Donham, Cristine, Doroudchi, M., Eaton, Kate, Edwards, Meredith, Eriksson, Annika, Essex, Anthony, Evans, Bradley, Evans, James, Evans, Kristin, Fiehn, Oliver, Fields, Jennifer, Fiering, Steven, Fontaine, Clinton, Fung, Juan, Gallagher, Curtis, Grant, Jeff, Greenfield, Edward, Griner, Erin, Gormally, Michael, Gupta, Archana, Hao, Haiping, Harr, Kaitlyn, Haselton, Michael, Hatakeyama, Jason, Hause, Ronald, Haven, Babette, Helfrich, Stefan, Hewitt, Alex, Hilton, Heidi, Horrigan, Stephen, Hou, Jeff, Huang, Chun-Teng, Incardona, Francesca, Ismail, Nawfal, Jin, Hyun Yong, Jones, Martina, Joy-Gaba, Jonathan, Judson, Robert, Kandela, Irawati, Kerwin, John, Khan, Israr, Kim, Jeewon, Kim, Young, KOSAKA, ALAN, Krieger, Teresa, Kwok, Jennie, LaBarge, Samuel, Lacoste, Judith, Lam, Matthew, Lesnik, Jake, Lewis, L. Michelle, Li, Jia, Lim, Minyoung, Lopez-Serra, Lidia, Maalouf, Samar, Mack, Hildegard, Maddox, Ewa, Maherali, Nimet, Mantis, Christine, Marrello, Sara, Mathur, Maya, McCarthy, Michael, McDonald, Elysia, Meyers, Zachary, Mitrofan, Claudia-Gabriela, Newell, Crystal, Newman, Stephanie, Northan, Brian, Owen, Katherine, Pandya, Kumar, Pedro, Luisa, Pelech, Steven, Pelletier, Vincent, Permaul, Eva, Peterson, Maureen, Phelps, Mitch, Pike, Amanda, Pineda, Javier, Pirani, Ali, Poe, Sara, Poindexter, Kevin, Polyzos, Aris, Pudlo, Nicholas, Radomska, Hanna, Raouf, Samrrah, Ratcliffe, Darrell, Ray, Courtney, Repass, John, Richardson, Adam, Rusckowski, Mary, Russler-Germain, David, Sampey, Darryl, Schaner Tooley, Christine, Scott, David, Sebastiano, Vittorio, Sen, Supti, Sengupta, Ranjita, Settles, Michael, Shakya, Reena, Shan, Xiaochuan, Shan, Yongli, Sharma, Vidhu, Sheen, Mee, Showalter, Megan, Skinner, Laura, Smith, Tim, Snitkin, Evan, Soderberg, Courtney, Statt, Sarah, Steelman, Brandon, Sutter, Catherine, Talbot, C., Tang, Beibei, Tolentino, Todd, Trinh, Angela, Unnikrishnan, Ashwin, Heuvel, Jack, Vandervorst, Kacey, Vasilevsky, Nicole, Veal, Mathew, Vowles, Chriss, Wang, Hongyan, Wang, Zhiyong, Weston, Claire, Willis, Brandon, Wilson, Ashley, Wood, Joshua, Woodard, Ben, Xin, Hong, Yan, Xuefei, Yang, Huajun, Yang, Wanwan, Young, Lisa, Yucel, Nora, Yue, Lambert, Zagnitko, Olga, Zervantonakis, Ioannis, and zhou, faren

Subjects
replication, open science, reproducibility, cancer biology
Abstract

We are conducting a study to investigate the replicability of cancer biology studies. Selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010-2012 are being replicated by the Science Exchange network.

Published
2022
Full Text
View/download PDF

2. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe

Author

Rossetti, Barbara, Fabbiani, Massimiliano, Di Carlo, Domenico, Incardona, Francesca, Abecasis, Ana, Gomes, Perpetua, Geretti, Anna Maria, Seguin-Devaux, Carole, Garcia, Federico, Kaiser, Rolf, Modica, Sara, Shallvari, Adrian, Sönnerborg, Anders, Zazzi, Maurizio, and EuResist Network, INTEGRATE study group

Subjects
integrase strand transfer inhibitors, Integrases, Health Policy, HIV, effectiveness, HIV Infections, treatment-experienced, HIV Integrase, Viral Load, INSTI, dolutegravir, Europe, Infectious Diseases, elvitegravir, raltegravir, Drug Resistance, Viral, Oxazines, Humans, Pharmacology (medical), HIV Integrase Inhibitors, Heterocyclic Compounds, 3-Ring
Abstract

To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects. Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated. Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5-3.8] in IN-NV, 18.4% (95% CI: 15.8-21.2) in IN-V, 4.2% (95% CI: 3.6-4.9) in IE-NV and 23.9% (95% CI: 20.9-26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1-13.0) in IN-NV, 19.6% (95% CI: 17.5-21.6) in IN-V, 10.8% (95% CI: 10.0-11.6) in IE-NV and 21.7% (95% CI: 19.7-23.5) in IE-V subjects. Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.

Published
2022

4. Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium

Author

Vinken, Lore, Fransen, Katrien, Cuypers, Lize, Alexiev, Ivailo, Balotta, Claudia, Debaisieux, Laurent, Seguin-Devaux, Carole, Ribas, Sergio G., Gomes, Perpétua, Incardona, Francesca, Kaiser, Rolf, Ruelle, Jean, Sayan, Murat, Paraschiv, Simona, Paredes, Roger, Peeters, Martine, Sönnerborg, Anders, Vancutsem, Ellen, Vandamme, Anne-Mieke, Van den Wijngaert, Sigi, Van Ranst, Marc, Verhofstede, Chris, Stadler, Tanja, Lemey, Philippe, and Van Laethem, Kristel

Subjects
Belgium, HIV-1, treatment as prevention, men-having-sex-with-men, phylodynamics, 3. Good health, sub-subtype F1
Abstract

Human immunodeficiency virus type 1 (HIV-1) non-B subtype infections occurred in Belgium since the 1980s, mainly amongst migrants and heterosexuals, whereas subtype B predominated in men-having-sex-with-men (MSM). In the last decade, the diagnosis of F1 sub-subtype in particular has increased substantially, which prompted us to perform a detailed reconstruction of its epidemiological history. To this purpose, the Belgian AIDS Reference Laboratories collected HIV-1 pol sequences from all sub-subtype F1-infected patients for whom genotypic drug resistance testing was requested as part of routine clinical follow-up. This data was complemented with HIV-1 pol sequences from countries with a high burden of F1 infections or a potential role in the global origin of sub-subtype F1. The molecular epidemiology of the Belgian subtype F1 epidemic was investigated using Bayesian phylogenetic inference and transmission dynamics were characterized based on birth-death models. F1 sequences were retained from 297 patients diagnosed and linked to care in Belgium between 1988 and 2015. Phylogenetic inference indicated that among the 297 Belgian F1 sequences, 191 belonged to a monophyletic group that mainly contained sequences from people likely infected in Belgium (OR 26.67, 95% CI 9.59–74.15), diagnosed in Flanders (OR 7.28, 95% CI 4.23–12.53), diagnosed at a recent stage of infection (OR 7.19, 95% CI 2.88-17.95) or declared to be MSM (OR 34.8, 95% CI 16.0–75.6). Together with a Spanish clade, this Belgian clade was embedded in the genetic diversity of Brazilian subtype F1 strains and most probably emerged after one or only a few migration events from Brazil to the European continent before 2002. The origin of the Belgian outbreak was dated back to 2002 (95% higher posterior density 2000–2004) and birth-death models suggested that its extensive growth had been controlled (Re < 1) by 2012, coinciding with a time period where delay in antiretroviral treatment initiation substantially declined. In conclusion, phylogenetic reconstruction of the Belgian HIV-1 sub-subtype F1 epidemic illustrates the introduction and substantial dissemination of viral strains in a geographically restricted risk group that was most likely controlled by effective treatment as prevention., Frontiers in Microbiology, 10, ISSN:1664-302X

Catalog

Books, media, physical & digital resources
See catalog results